 NEW YORK, Dec. 01, 2022 GLOBE NEWSWIRE -- Cellectis the Company Euronext Growth: ALCLS - NASDAQ: CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Companys clinical data on the AMELI-01 study evaluating UCART123 presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022. 